Our mission is to be a world leader in the discovery and development of unique and innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Recognised as one of the companies at the forefront of HIV research, Janssen Infectious Diseases has three antiretroviral compounds for the treatment of HIV - a novel protease inhibitor (PI) and two non-nucleoside reverse transcriptase inhibitor (NNRTI) that have been approved by FDA in US and EMEA for the European Union and several other countries around the world.

In 2011 a new product was approved for the treatment of Genotype 1 Hepatitis C: a Direct Acting Antiviral (DAA), which is a type of drug that targets specific enzymes to block important stages of replication of the HCV virus. By interfering with viral replication, DAAs have the potential to help cure patients of their HCV infection.

Furthermore does the company also have an anti-tuberculosis compound from a novel class in development, and active discovery programs in HIV, Hepatitis C and other life-threatening infectious diseases.

Janssen Infectious Diseases is committed to improving medical care as well as the quality and longevity of life for patients.